Too many useless back and forth. Too much blame, too much bashing...there's one simple fix that Gerald can do for shareholders: BUY BACK SHARES TO LOWER THE FLOAT.
Way too many shares on the float right now. During downtrends and periods of low buying, this makes for a perfect short or a stock to manipulate. In other words, this is more of a technical problem, rather than a fundamental one (for those of you scratching your heads on why the stock seems to be going the opposite way than the companies asset progress).
He can either do a R/S or a buyback. R/S is definitely the easiest, but would destroy shareholders even more. So buyback would be the best to address the technical problem while benefiting shareholders. Well, to do a buyback, you'd need cash and the best way right now is, as everyone's been talking about, a spinoff.
To get the MOST value out of a spinoff of the diagnostics would be to get CLIA done and execute some more contracts for Lympro. Along with Diogenix and some other licenses, the company should be able to get at least 20-50M (rough estimate, don't quote me on this, just throwing numbers around here).
A simple buyback at this point would not only fix the SOS problem and CREATE shareholder value. It's the only way in the short-term of addressing the technical problem (besides blind hoping MANF cures cancer or something). The question now is if you trust management to execute this plan. It seems to be their intention as well.
Potential cash from Diogenix on books ~$7M, bought for $10M
ESS cash value $10M
Given, the company's current market cap of ~40MM assuming 850Mish something shares outstanding, market is giving Lympro, MANF, and Eltoprazine a value of $20M
Didn't realize not having news for 30 days made MANF, Lympro, and Eltoprazine all so worthless
Stock price going through a cycle, could we see 4's, 3's? Maybe...but I'll be selling my car to buy more shares at that price. 750MM shares float, LPC only has ~5M shares as of 09/03/2014 (4M shares at .04 and 1.5M at around ~0.9).
Don't blame it on LPC, they probably have less shares issued than smitty ;) And don't forget, the LPC deal is still in place with MOST of the line available.
Also, look at some of the companies presenting in the April conference, sure...not much news may come out of that, but check out some the other companies, the one above AMBS is backed by google ventures.
W/e happens, good luck and I hope everyone makes a lot of money, 'cause thats what all these BS posting is here to serve.
Longs worried about something not fundamental. They see some drops and they get scared and sell.
Stock movement's actually been very predictable. During quiet periods, traders will take over...if it gets to a resistant level they sell and support they buy. With relatively low volume and a large float, this aint gonna be making any major moves. I'm loving it though, every 2 weeks I get my paycheck, if the price is good, I buy some.
I am still very positive on the company and I think it will eventually break above .20 given enough volume and good news. I think possible catalysts for that may come around Q1 next year given enough for the company to execute some contracts with Lympro after CLIA and FDA response to Eltoprazine, MANF. ESS is going through some trials.
It's your money though, I wouldn't listen to jokers on this board (including myself ;)
Lympro has no direct commercially available competitor
It's not yet fully commercialized (CLIA and eventual FDA)
It's building out its platform and positioning itself strategically horizontally by incorporating likely competitive tests such as the Georgetown test and attracting key leaders in this area
The platform will eventually seek to combine both DX and Therapeutics
Other biomarkers are available to potentially create version 3, 4, 5...this is a work-i- progress
First customer LOI signed, which is a significant milestone
This is what I'm talking about by people making #$%$ up on this board...no valid argument and just tries to spread fear.
No real news for longer than what people are used to, so people start making up stuff and traders take over. It's going to be up and down during these periods. AMBS isn't CNN, it's not gonna be releasing news everyday, they still need time to develop assets. Don't become so obsessed over small details or a stock, it'll come to hurt you.
I haven't said anything on this board for a while now as there's nothing but fighting. Been a strong supporter of the company for two years now. I was here when the company only had 3 people on there management team and I was here for MANF. The amount of growth I saw since then has been impressive and it's made the company a lot stronger....which is why I am so impressed.
Seems like all the day traders forgot the diogenix deal already. The management's ability to source and EXECUTE deals has simply been an overlooked part of the story, purely amazing for a $60M company.
As far as a biotech company goes, AMBS has all the ingredients for success: Deep pipeline, positive catalysts, potential revenue, and more importantly a rock-star management team with significant scientific and transaction expertise that is on par with middle market private equity firms.
For all the people who has been apart of the story for more than 2 years...look back, there has not been ANY negative news on the pipeline....there were setbacks and disappointments, but good results continue to come.
This is very exciting, I think the next 5 years will be very exciting and I plan to stick around when all current pipeline are Phase III or beyond. That's when the real money will be made.
True value inflection for Lympro will be after CLIA as I've said in an earlier post. Revenue is secondary to CLIA and other major milestones at this point.
If the market isn't valuing the sum of parts correctly, sell a percentage of one of the parts to get a more accurate valuation. Example: sell 20% of diagnostics at $20M, instantly gives the division a $100M valuation.
Instant cash and more accurate valuation for sum of part. Shareholders and hold co. continue to hold rights to future revenues. Very simple, low risk, and quick turnaround. That will be the spin-off.
Good to put things in perspective once in a while instead of bickering with all these people with hidden agendas :)
I have nothing more of value to say or contribute to this board. Maybe pop back in here and there once a while.
It's become increasingly obvious in the past few months that very few people has any idea what kind strategies the Company is planning. GC has been secretive and he's doing deals left and right internally, which is amazing for a small biotech - speaks volumes to the depths of knowledge of the Management, BOA & BOD.
Growth potential will be amazing these next two years and I know a lot of good things will happen. I'll be holding long and strong.
Good luck all!!! (block smitty if you haven't already ;)
New Lympro Data cannot skew previous results that significantly, most likely will improve asset accuracy. Way too much support to reach what you are predicting.
JPM conference will be a non-event for share price, possibly slowly move to $0.1 if data continues to support what we know. True value inflection will probably come around march - may when we hear more about CLIA, RUO revenue, second MANF ODD, ESS option...etc.
2015 will be the year of LymPro
2016-2018 will be the year of ESS and MANF
Don't know why smitty bothers to manipulate this stock, absolutely no volume right now. He's definitely in it for the long run.
You miss the point, it's not failure. It's lack of communication and misdirection from a shareholders' standpoint. Gerald's first reaction after making a mistake is to shift blame and that has NOT changed.
I will answer that question right now. No, not until LymPro at least gets certified by CLIA. RUO is not a reputable standard for large pharmas.
What I'm looking for is for these idiots to take their heads out of their #$%$. These people are so afraid of losing money they don't dare to even question what if.
Thumbs me down more...wonder how long you really gonna defend Gerald through another 60% drop?
Yea, according to KOLs, it's in the shareholders' best interest to do this at the JPM conference.